Forschung

Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
···

Warum die SLS-Aktie im vorbörslichen Handel steigt: SELLAS Life Sciences bringt den Countdown für die REGAL-Phase-3-Studie wieder ins Spiel

SELLAS Life Sciences stieg vorbörslich am Montag um 3,4 % auf $4,29, während der SPDR S&P Biotech ETF um 1,5 % fiel. Am Freitag schloss die Aktie bei $4,15 nach starkem Handel. Händler warten auf das 80. Ereignis in der Phase-3-AML-Studie, das Mitte März erwartet wird. Die Short-Quote liegt bei 24,42 % des Streubesitzes.
Februar 23, 2026

Stock Market Today

  • Diploma Plc: £10,000 in FTSE 100 Stock Grew to £23,959 Over 5 Years
    May 25, 2026, 11:41 AM EDT. Diploma Plc (LSE:DPLM) has been a top FTSE 100 performer, turning a £10,000 investment five years ago into £23,959. The company reported 17% revenue growth and a 36% rise in earnings per share recently, driven largely by its Controls division, which benefits from increased defence spending and data centre demand. Despite this strong performance, risks persist due to the company's reliance on cyclical markets like aerospace and data centres. With a high price-to-earnings (P/E) ratio around 31, the stock could face sharp declines if demand falters. Analysts urge caution, noting that the firm's target of 5% annual organic growth may not justify its current valuation.